These observations were also validated in MDA-MB-231 paclitaxel-resistant breast cancer cells, where higher levels of EDIL3 and SDC2 indicated the involvement of the EMT process in paclitaxel resistance, as reported in ovarian cancer38,39. The gene discussed is SDC2; the disease is breast cancer.